Your Patients Need Afrezza — Here's How to Help Them Get It

You've prescribed Afrezza because your patient is a good candidate for inhaled insulin. Maybe they have needle fatigue, poor mealtime adherence with injectable rapid-acting insulins, or they've experienced problematic late hypoglycemia with their current regimen. Whatever the clinical rationale, Afrezza offers a differentiated option — ultra-rapid onset, needle-free delivery, and a pharmacokinetic profile that mirrors natural first-phase insulin release.

But then the patient calls back: "My pharmacy doesn't carry it." Or worse, they simply don't fill the prescription and show up at their next appointment with uncontrolled postprandial glucose. The access barrier became an adherence barrier.

This guide provides actionable steps your practice can take to help patients successfully find and fill their Afrezza prescriptions.

Current Availability Landscape

As of 2026, Afrezza is not in a formal shortage. MannKind Corporation continues to manufacture all three cartridge strengths (4-unit, 8-unit, and 12-unit) and the Afrezza Inhaler device.

The access challenge is at the retail pharmacy level:

• Most chain pharmacy locations (CVS, Walgreens, Rite Aid) do not routinely stock Afrezza
• Afrezza can be special-ordered through wholesalers, typically arriving in 1-3 business days
• Independent pharmacies and specialty pharmacies are more likely to maintain regular stock
• MannKind's Direct Purchase Program ships directly to patients via Eagle Pharmacy

For the full supply picture, see our provider-focused shortage update.

Why Patients Can't Find Afrezza

Understanding the root causes helps you anticipate and address patient concerns:

Low Pharmacy Stocking Rates

Afrezza has a relatively small commercial patient base compared to injectable insulins. With perhaps one or two patients per pharmacy location needing Afrezza, most chains don't justify keeping it on the shelf. The product requires refrigeration for unopened cartridges and has specific handling protocols — additional factors that reduce pharmacy willingness to maintain inventory.

Insurance Friction

Prior authorization requirements affect approximately 70-80% of Afrezza prescriptions. Many commercial plans also impose step therapy. This creates a chicken-and-egg problem: pharmacies don't stock what they rarely dispense, and patients struggle to fill what pharmacies don't stock. The administrative burden of prior authorizations often delays fills by 3-10 business days.

Patient Knowledge Gaps

Many patients don't know they have options beyond their local chain pharmacy. They may not be aware of specialty pharmacies, MannKind's direct delivery program, or tools like Medfinder that can locate stocking pharmacies. Patient education at the point of prescribing is critical.

What Providers Can Do: 5 Actionable Steps

Step 1: Set Expectations at the Point of Prescribing

When you write an Afrezza prescription, proactively tell your patient:

• "Your regular pharmacy may not stock this — it's a specialty medication"
• "Here are pharmacies that typically carry it" (provide 2-3 options)
• "If your pharmacy needs to order it, give them 3-5 days' notice for refills"
• "There's also a direct delivery option if local pharmacies don't work out"

This simple conversation can prevent the most common reason patients don't fill Afrezza: they try one pharmacy, get turned away, and give up.

Step 2: Initiate Prior Authorization Proactively

Don't wait for the pharmacy to trigger the PA. Submit prior authorization at the time of prescribing or within 24 hours. Include:

• Clinical rationale for inhaled insulin (adherence concerns, needle phobia, injection site reactions, postprandial glucose pattern)
• Documentation of prior mealtime insulin therapy (for step therapy requirements)
• Baseline spirometry (FEV1) results confirming no chronic lung disease
• Smoking status and history
• A1C and glucose monitoring data showing need for mealtime insulin optimization

Many practices find it helpful to create a standardized PA template for Afrezza that staff can quickly complete, reducing turnaround from days to same-day in many cases.

Step 3: Establish Specialty Pharmacy Relationships

Identify 1-2 specialty pharmacies in your area that reliably stock Afrezza and maintain a working relationship with them:

• Provide their contact information directly to patients at the time of prescribing
• Send prescriptions electronically to the specialty pharmacy (not just to the patient's "default" chain pharmacy)
• Ask the specialty pharmacy to handle PA processing when possible — many have dedicated teams for this

If your practice doesn't have specialty pharmacy connections, start by asking MannKind's provider support line (844-323-7399) for local recommendations.

Step 4: Educate Patients on Alternative Fill Options

Equip your patients with multiple paths to fill their prescription:

• Medfinder: Direct patients to search for pharmacies near them with Afrezza in stock
• MannKind Direct Purchase: $99/month shipped to their home via Eagle Pharmacy — ideal for cash-paying patients or those in areas with limited pharmacy options
• Mail-order pharmacy: Available through many commercial and Medicare Part D plans for 90-day supply delivery
• Afrezza Savings Card: Commercially insured patients can pay as little as $35/fill — enroll at afrezza.com/savings-program

Consider creating a patient handout with these resources that your front desk or diabetes educator can distribute at the visit.

Step 5: Follow Up Within 7-10 Days

A brief follow-up call or patient portal message within 7-10 days of prescribing can catch access problems early:

• "Were you able to fill your Afrezza prescription?"
• "Do you need help with prior authorization or finding a pharmacy?"
• "Have you had a chance to try the inhaler? Any questions about technique?"

This simple touchpoint can be the difference between a patient who starts Afrezza successfully and one who falls through the cracks.

Alternative Mealtime Insulin Options

If Afrezza is not accessible or appropriate for a specific patient, the following rapid-acting insulins serve as alternatives:

• Lyumjev (Insulin Lispro-aabc): Ultra-rapid-acting injectable with the fastest onset among injectables (5-10 minutes). Closest match to Afrezza's speed profile.
• Humalog (Insulin Lispro): Well-established rapid-acting insulin. Generic versions available at significantly lower cost ($25-50/vial).
• NovoLog (Insulin Aspart): Another widely used rapid-acting option with biosimilar availability.
• Apidra (Insulin Glulisine): Less commonly used but effective rapid-acting alternative.

For patients whose primary barrier is needle aversion, explore whether the clinical rationale supports continuing to pursue Afrezza access rather than defaulting to an injectable alternative that may compromise adherence.

For a patient-facing comparison, see our article on alternatives to Afrezza.

Workflow Tips for Your Practice

Integrating Afrezza access support into your workflow doesn't have to be complicated:

• Build PA templates: Create reusable prior authorization templates with standard clinical language for Afrezza. Include checkboxes for common justifications.
• Train support staff: Ensure your medical assistants and front desk staff know how to direct Afrezza patients to specialty pharmacies, MannKind support, and Medfinder.
• Track fill rates: Periodically check how many Afrezza prescriptions are actually being filled vs. abandoned. High abandonment rates signal an access problem your practice can address.
• Keep samples: If available from your MannKind representative, keep starter samples on hand to bridge patients while PA or pharmacy ordering is in progress.
• Provide printed resources: Give patients the MannKind Direct Purchase number (844-323-7399), the Afrezza Savings Card website, and the Medfinder URL at the point of care.

Final Thoughts

Afrezza is a valuable tool in the diabetes management arsenal — but its value is only realized when patients can actually access it. The distribution challenges surrounding Afrezza are real but solvable with proactive prescriber engagement.

By setting expectations, streamlining prior authorizations, connecting patients with the right pharmacies and savings programs, and following up on fills, you can dramatically improve the chances that your Afrezza patients actually start and stay on therapy.

For more provider resources, visit Medfinder for Providers. For guidance on helping patients manage costs, see our provider's guide to saving money on Afrezza.